Teachers Retirement System of The State of Kentucky Acquires 8,280 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Teachers Retirement System of The State of Kentucky boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 296.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,070 shares of the company's stock after purchasing an additional 8,280 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in TransMedics Group were worth $690,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Vanguard Group Inc. increased its holdings in TransMedics Group by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock valued at $226,700,000 after purchasing an additional 40,860 shares during the period. FIL Ltd increased its stake in shares of TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after buying an additional 218,961 shares during the period. Geode Capital Management LLC increased its stake in shares of TransMedics Group by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 772,744 shares of the company's stock valued at $48,191,000 after buying an additional 8,954 shares during the period. Wasatch Advisors LP raised its holdings in shares of TransMedics Group by 83.3% during the fourth quarter. Wasatch Advisors LP now owns 441,354 shares of the company's stock valued at $27,518,000 after acquiring an additional 200,603 shares in the last quarter. Finally, Emerald Advisers LLC lifted its stake in TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock worth $23,176,000 after acquiring an additional 220,804 shares during the period. Institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on TMDX shares. Piper Sandler restated an "overweight" rating and issued a $105.00 price objective (up from $90.00) on shares of TransMedics Group in a report on Tuesday. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $124.20.

TransMedics Group Stock Down 0.5 %

TransMedics Group stock traded down $0.47 during mid-day trading on Friday, hitting $89.98. The company had a trading volume of 682,568 shares, compared to its average volume of 1,330,359. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a market capitalization of $3.04 billion, a PE ratio of 95.72 and a beta of 2.14. The stock's 50 day moving average price is $75.68 and its two-hundred day moving average price is $77.01. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.